Читать книгу Assisted Reproduction Techniques - Группа авторов - Страница 152

1 1 The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Authors: Fauser B, Tarlatzis B, Chang J, Azziz R, Legro R, Dewailly D, Franks S, Balen AH, Bouchard P, Dahlgren E, Devoto, Diamanti E, Dunaif A, Filicori M, Homburg R, Ibanez L, Laven J, Magoffin D, Nestler J, Norman R, Pasquali R, Pugeat M, Strauss J, Tan SL, Taylor A, Wild R, Wild S. Human Reproduction 2004; 19: 41–47.

2 2 Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Misso ML, Moran L, Piltonen T, Norman RJ on behalf of the International PCOS Network. Recommendations from the international evidence‐based guideline for the assessment and management of polycystic ovary syndrome. Simultaneous publication: Fertility and Sterility, 2018; 110:364–379; Clinical Endocrinology, 2018; 89: 251–268; Human Reproduction, 2018; 33:1602–1618.

3 3 Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, Stener‐Victorin E, Norman RJ, Fauser BJCM, Teede H. WHO recommendations for The Management of Anovulatory Infertility in Women with Polycystic Ovary Syndrome (PCOS), Human Reproduction Update 2016; 22: 687–708 doi: 10.1093/humupd/dmw 025.

4 4 Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017 Jan 23; 1:CD012103. doi: 10.1002/14651858.CD012103.pub2.

5 5 Sha T, Wang X, Cheng W, Yan Y.A meta‐analysis of pregnancy‐related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. Reprod Biomed Online. 2019 Aug; 39(2):281–293. doi: 10.1016/j.rbmo.2019.03.203. Epub 2019 Mar 29.

6 6 van Wely, M., et al., Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011;( 2): CD005354.

7 7 Tso LO, Costello MF, Albuquerque LET, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;CD006105.

8 8 Al‐Inany HG, Youssef MA, Ayeleke R, Brown J, Lam W, Broekmans FJ. Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Syst Rev. 2016, Issue 4. Art. No.: CD001750. DOI:10.1002/14651858.CD001750.pub4

9 9 Youssef MAFM, Van der Veen F, Al‐Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al. Gonadotropin‐releasing hormone agonist versus HCG for oocyte triggering in antagonist‐assisted reproductive technology. Cochrane Database Syst Rev. 2014;CD008046.

10 10 Haahr T, Roque M, Esteves SC, Humaidan P. GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cycles‐A Systematic PRISMA Review and Meta‐analysis. Front Endocrinol (Lausanne). 2017; 8:116.

11 11 Devroey P, Polyzos NP, Blockeel C. An OHSS‐Free Clinic by segmentation of IVF treatment. Hum Reprod. 2011; 26:2593–7.

12 12 Chen Z‐J, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, et al. Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2016; 375:523–33.

13 13 Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi‐Engbeaya C, Nijher GMK, et al. Efficacy of Kisspeptin‐54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During in vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab. 2015; 100:3322–31.

14 14 Siristatidis CS, Maheshwari A, Vaidakis D, Bhattacharya S. in vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev. 2018 Nov 15; 11:CD006606. doi: 10.1002/14651858.CD006606.pub4.

15 15 Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017 Jan 23; 1:CD012103. doi: 10.1002/14651858.CD012103.pub2.